Major advances in supportive care and HCT practice in the past decade have resulted in expanded indications and a significant survival benefit for pediatric patients undergoing allogeneic HCT, according to a single-center study of 250 children and adolescents transplanted between 1983 and 2010. Five-year overall survival was significantly higher in 2000-2010 compared to 1983-1999 (64% vs. 52%, respectively; p=0.03), and non-relapse mortality was significantly lower (9% vs. 27%, respectively; p=0.0002). There was a trend toward higher progression-free survival (57% vs. 49%, respectively) but this was not significant (p=0.17). The authors note that incorporating novel therapeutic advances for better control of pre-HCT disease and improved post-care management is needed to address relapse rates.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Better HCT Outcomes Over Time in Children and Adolescents
Mar 2016